A Case Report: Outpatient Care & Recognizing the Complications of Systemic Lupus Erythematosus
Main Article Content
Abstract
The objective of this case study is to study one patient’s trajectory from diagnosis to complications of Systemic Lupus Erythematosus that spanned 40 years. A discussion of the disorder will be explained as well as diagnosis and treatment. As an autoimmune disorder, this form of lupus triggers symptoms that make it difficult to pinpoint the diagnosis initially. Early diagnosis and treatment are paramount to managing the progression of lupus. Systemic Lupus Erythematosus can cause complications of infection, renal disease and heart failure. Treatment regimen themselves can cause untoward complications for patients if not managed closely. Through effective medical management of symptoms, regularly scheduled appointments which include lab evaluation and consulting specialists in monitoring these complications, patients can live an optimal quality of life. This case report is an example of a patient who received outpatient care which maintained her quality of life for many years with complications of renal failure and cardiogenic shock occurring later in life. This case serves as an example of one patient’s journey through systemic lupus erythematosus from a medical standpoint and the complications that can occur. Effective outpatient management of Systemic Lupus Erythematosus and when complications arise can help alleviate symptoms and promote optimal quality of life.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. National Resource Center on Lupus. Lupus Facts and Statistics. National Resource Center on Lupus. Published 2025. Accessed September 19, 2025. https://www.lupus.org/resources/lupus-facts-and-statistics
3. Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC. Pathogenesis of human systemic lupus erythematosus: A cellular perspective. Trends Mol Med. 2017;23(7):615-635. doi:10.1016/j.molmed.2017.05.006
4. Justiz Vallant AA, Goyal A, Varacallo MA. Systemic Lupus Erythematosus. In: StatPearls. StatPearls Publishing; 2025. Accessed October 2, 2025. PMID: 30571026.
5. Katarzyna PB, Wiktor S, Ewa D, Piotr L. Current treatment of systemic lupus erythematosus: a clinician's perspective. Rheumatol Int. 2023;43(8):1395-1407. doi:10.1007/s00296-023-05306-5
6. Alarcón GS, Ugarte-Gil MF, Pons-Estel G, Vila LM, Reveille JD, McGwin G. Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII), a multiethnic, multicenter US cohort. Lupus. 2019;28:423-426. doi:10.1177/0961203319826693
7. Pakchotanon R, Gladman DD, Su J, Urowitz M. Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease, and end-stage renal disease in lupus nephritis. Lupus. 2018;27:468-474. doi:10.1177/0961203317726376
8. Alves P, Bashir MM, Wysocka M, Zeidi M, Feng R, Werth VP. Quinacrine suppresses tumor necrosis factor-α and IFN-α in dermatomyositis and cutaneous lupus erythematosus. J Invest Dermatol Symp Proc. 2017;18:S57-S63. doi:10.1016/j.jips.2016.11.001
9. Chiavolini, D. Comorbidities in autoimmune disease and Multiple Autoimmune Syndrome. Global Autoimmune Institute: Empowering Solutions. 2025. Retrieved October 14, 2025 from https://www.autoimmuneinstitute.org/articles/comorbidities-in-autoimmune-disease-multiple-autoimmune-syndrome/
10. Mosca M, Bruce IN, Andersen J, Ugarte-Gil MF, Arnaud L. Challenges and opportunities in access to care for systemic lupus erythematosus patients across Europe and worldwide. Rheumatology (Oxford). 2024;63(7):1772-1778. doi:10.1093/rheumatology/keae227
11. Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: Trends over time and major contributors. Rheumatology (Oxford). 2020 Dec 5;59(Suppl5):v29-v38. doi: 10.1093/rheumatology/keaa382
12. Dunkin M. Lupus tests. Arthritis Foundation. Published 2022. Accessed September 26, 2025. https://www.arthritis.org/health-wellness/about-arthritis/understanding-arthritis/lupus-testing
13. Foundation of the American Society of Retina Specialists. Hydroxychloroquine-induced retinal toxicity. Retina Health Series. Published 2025. Accessed September 26, 2025. https://www.asrs.org/patients/retinal-diseases/45/hydroxychloroquine-induced-retinal-toxicity
14. Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018;41:919-931. doi:10.1007/s40264-018-0689-4
15. Vaidya, SR, Aeddula, NR. Chronic Kidney Disease. In: StatPearls. StatPearls Publishing; 2025. Updated July 31, 2024. Accessed October 2, 2025. https://www.ncbi.nlm.nih.gov/books/NBK535404/
16. Dein, E, Douglas, H, Petri, M, Law, G, Timlin, H. Pericarditis in Lupus. Cureus. 2019 Mar 1;11(3):e4166. doi: 10.7759/cureus.4166
17. Kim, YJ, Lovell, J, Diab, A, Magde,r LS, Goldman, D, Petr,i M, Fava, A & Adamo, L. Incidence and Factors Associated With Recurrent Pericarditis in Lupus. JAMA Netw Open. 2025 Feb 3;8(2):e2461610. doi: 10.1001/jamanetworkopen.2024.61610
18. Moder, KG, Miller, TD, & Tazelaar, HD: Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc. 1999, 74:275-284. 10.4065/74.3.275
19. Amro, AM, Deeb, S, Rije, R, Deeb, N, Qunaibi, YY, Amr, B, Irzeqat, K, Alhadad, B, & Emar A. Systemic Lupus Erythematosus Presenting as Cardiac Tamponade and Pleural Effusion: A Case Report. Cureus. 2024 Jan 25;16(1):e52894. doi: 10.7759/cureus.52894
http://orcid.org/0000-0002-9288-6077